Ontology type: schema:ScholarlyArticle Open Access: True
2018-12
AUTHORSChristine Årdal, Enrico Baraldi, Ursula Theuretzbacher, Kevin Outterson, Jens Plahte, Francesco Ciabuschi, John-Arne Røttingen
ABSTRACTBackground: Antibiotic innovation has dwindled to dangerously low levels in the past 30 years. Since resistance continues to evolve, this innovation deficit can have perilous consequences on patients. A number of new incentives have been suggested to stimulate greater antibacterial drug innovation. To design effective solutions, a greater understanding is needed of actual antibiotic discovery and development costs and timelines. Small and medium-sized enterprises (SMEs) undertake most discovery and early phase development for antibiotics and other drugs. This paper attempts to gather a better understanding of SMEs' targets, costs, and durations related to discovery and early phase development of antibacterial therapies. Methods: DRIVE-AB, a project focused on developing new economic incentives to stimulate antibacterial innovation, held a European stakeholder meeting in February 2015. All SMEs invited to this meeting (n = 44) were subsequently sent a survey to gather more data regarding their areas of activity, completed and expected development costs and timelines, and business models. Results: Twenty-five companies responded to the survey. Respondents were primarily small companies each focusing on developing 1 to 3 new antibiotics, focused on pathogens of public health importance. Most have not yet completed any clinical trials. They have reported ranges of discovery and development out-of-pocket costs that appear to be less expensive than other studies of general pharmaceutical research and development (R&D) costs. The duration ranges reported for completing each phase of R&D are highly variable when compared to previously published general pharmaceutical innovation average durations. However, our sample population is small and may not be fully representative of all relevant antibiotic SMEs. Conclusions: The data collected by this study provide important insights and estimates about R&D in European SMEs focusing on antibiotics, which can be combined with other data to design incentives to stimulate antibacterial innovation. The variation implies that costs and durations are difficult to generalize due to the unique characteristics of each antibiotic project and depend on individual business strategies and circumstances. More... »
PAGES8
http://scigraph.springernature.com/pub.10.1186/s40545-018-0135-0
DOIhttp://dx.doi.org/10.1186/s40545-018-0135-0
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1103128502
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/29632669
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1503",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Business and Management",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/15",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Commerce, Management, Tourism and Services",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Norwegian Institute of Public Health",
"id": "https://www.grid.ac/institutes/grid.418193.6",
"name": [
"Norwegian Institute of Public Health, Postboks 4404 Nydalen, 0403, Oslo, Norway"
],
"type": "Organization"
},
"familyName": "\u00c5rdal",
"givenName": "Christine",
"id": "sg:person.0657474211.42",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657474211.42"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Uppsala University",
"id": "https://www.grid.ac/institutes/grid.8993.b",
"name": [
"Uppsala University, Box 513, 751 20, Uppsala, Sweden"
],
"type": "Organization"
},
"familyName": "Baraldi",
"givenName": "Enrico",
"id": "sg:person.014147724211.48",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014147724211.48"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"Center for Anti-Infective Agents, Vienna, Austria"
],
"type": "Organization"
},
"familyName": "Theuretzbacher",
"givenName": "Ursula",
"id": "sg:person.0610347730.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610347730.20"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Boston University",
"id": "https://www.grid.ac/institutes/grid.189504.1",
"name": [
"Boston University, 765 Commonwealth Avenue, 02215, Boston, MA, USA"
],
"type": "Organization"
},
"familyName": "Outterson",
"givenName": "Kevin",
"id": "sg:person.0635205222.54",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635205222.54"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Norwegian Institute of Public Health",
"id": "https://www.grid.ac/institutes/grid.418193.6",
"name": [
"Norwegian Institute of Public Health, Postboks 4404 Nydalen, 0403, Oslo, Norway"
],
"type": "Organization"
},
"familyName": "Plahte",
"givenName": "Jens",
"id": "sg:person.01271753243.42",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271753243.42"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Uppsala University",
"id": "https://www.grid.ac/institutes/grid.8993.b",
"name": [
"Uppsala University, Box 513, 751 20, Uppsala, Sweden"
],
"type": "Organization"
},
"familyName": "Ciabuschi",
"givenName": "Francesco",
"id": "sg:person.011055342653.42",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011055342653.42"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"Norwegian Institute of Public Health, University of Oslo, Postboks 4404 Nydalen, 0403, Boks 1072 Blindern, 0316, Oslo, Norway"
],
"type": "Organization"
},
"familyName": "R\u00f8ttingen",
"givenName": "John-Arne",
"id": "sg:person.01207073626.16",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207073626.16"
],
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1016/s0140-6736(15)00474-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003178984"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1128/cmr.00030-10",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1006875263"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nrd.2016.229",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1009460305",
"https://doi.org/10.1038/nrd.2016.229"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1057/biosoc.2010.40",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1010750210",
"https://doi.org/10.1057/biosoc.2010.40"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nrd3078",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1016256401",
"https://doi.org/10.1038/nrd3078"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nrd3078",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1016256401",
"https://doi.org/10.1038/nrd3078"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s1473-3099(13)70318-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1018650635"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/jac/dkv020",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1023906984"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s1473-3099(15)00500-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1026058493"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/ja.2015.98",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1027730298",
"https://doi.org/10.1038/ja.2015.98"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1126/science.1254163",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1027827915"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.drudis.2014.07.005",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031649204"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.jhealeco.2016.01.012",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1042169659"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1377/hlthaff.2014.1003",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1048299986"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.7326/m16-0291",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1073743011"
],
"type": "CreativeWork"
}
],
"datePublished": "2018-12",
"datePublishedReg": "2018-12-01",
"description": "Background: Antibiotic innovation has dwindled to dangerously low levels in the past 30\u00a0years. Since resistance continues to evolve, this innovation deficit can have perilous consequences on patients. A number of new incentives have been suggested to stimulate greater antibacterial drug innovation. To design effective solutions, a greater understanding is needed of actual antibiotic discovery and development costs and timelines. Small and medium-sized enterprises (SMEs) undertake most discovery and early phase development for antibiotics and other drugs. This paper attempts to gather a better understanding of SMEs' targets, costs, and durations related to discovery and early phase development of antibacterial therapies.\nMethods: DRIVE-AB, a project focused on developing new economic incentives to stimulate antibacterial innovation, held a European stakeholder meeting in February 2015. All SMEs invited to this meeting (n\u2009=\u200944) were subsequently sent a survey to gather more data regarding their areas of activity, completed and expected development costs and timelines, and business models.\nResults: Twenty-five companies responded to the survey. Respondents were primarily small companies each focusing on developing 1 to 3 new antibiotics, focused on pathogens of public health importance. Most have not yet completed any clinical trials. They have reported ranges of discovery and development out-of-pocket costs that appear to be less expensive than other studies of general pharmaceutical research and development (R&D) costs. The duration ranges reported for completing each phase of R&D are highly variable when compared to previously published general pharmaceutical innovation average durations. However, our sample population is small and may not be fully representative of all relevant antibiotic SMEs.\nConclusions: The data collected by this study provide important insights and estimates about R&D in European SMEs focusing on antibiotics, which can be combined with other data to design incentives to stimulate antibacterial innovation. The variation implies that costs and durations are difficult to generalize due to the unique characteristics of each antibiotic project and depend on individual business strategies and circumstances.",
"genre": "research_article",
"id": "sg:pub.10.1186/s40545-018-0135-0",
"inLanguage": [
"en"
],
"isAccessibleForFree": true,
"isFundedItemOf": [
{
"id": "sg:grant.4639944",
"type": "MonetaryGrant"
}
],
"isPartOf": [
{
"id": "sg:journal.1045870",
"issn": [
"2052-3211"
],
"name": "Journal of Pharmaceutical Policy and Practice",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "11"
}
],
"name": "Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations",
"pagination": "8",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"fdbcbbfb0b39f58f90ae137453f920fcbed78e2bc4512a0703022a45f9387828"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"29632669"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"101627192"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s40545-018-0135-0"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1103128502"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s40545-018-0135-0",
"https://app.dimensions.ai/details/publication/pub.1103128502"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-11T13:54",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130808_00000005.jsonl",
"type": "ScholarlyArticle",
"url": "https://link.springer.com/10.1186%2Fs40545-018-0135-0"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40545-018-0135-0'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40545-018-0135-0'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40545-018-0135-0'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40545-018-0135-0'
This table displays all metadata directly associated to this object as RDF triples.
168 TRIPLES
21 PREDICATES
43 URIs
21 LITERALS
9 BLANK NODES